Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy
Membranous nephropathy (MN) is a common pathological type of adult nephrotic syndrome. According to the etiology, MN is divided into idiopathic membranous nephropathy (IMN) and secondary membranous nephropathy (SMN). IMN accounts for around 80% of MN patients. Glucocorticoid plus alkylating agents o...
Main Authors: | Chao Zhang, Hui Liao, Rong-shan Li |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Nephrology
2024-01-01
|
Series: | Linchuang shenzangbing zazhi |
Subjects: | |
Online Access: | http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2024.01.010 |
Similar Items
-
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
by: Maxime Teisseyre, et al.
Published: (2021-10-01) -
Research advances of factors and mechanisms for therapeutic efficacy of rituximab for primary membranous nephropathy
by: Yu-ting Liu, et al.
Published: (2024-09-01) -
Rituximab in Membranous Nephropathy
by: Philipp Gauckler, et al.
Published: (2021-04-01) -
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach
by: Song Wang, et al.
Published: (2023-05-01) -
Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection
by: Xiaodan Li, et al.
Published: (2024-09-01)